Semaglutide for the Treatment of Cannabis Use Disorder

Study acronym: S-CUD
StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this pilot study is to learn about the effects of semaglutide on brain reactivity to cannabis-related cues in adults with cannabis use disorder. The main questions it aims to answer are: 1. Does semaglutide effect reactivity to cannabis-related cues? 2. Does semaglutide safely reduce the frequency of cannabis use? Participants will complete five in-person study visits over 9 weeks, which will include interviews, questionnaires, and collection of biological samples for laboratory testing. fMRI scans will be completed at two visits. All participants will receive weekly injections of 0.25-0.5 mg semaglutide across 8 weeks.
Trial Details
NCT Number NCT07879612
Lead Sponsor Massachusetts General Hospital
Collaborators: Brigham and Women's Hospital
Conditions
(from sponsor)		 Cannabis Use Disorder, Cue-reactivity
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov